Evidence map›Paper›PMID 29938004›Full record

ArticleOncotarget2018

High miR-100 expression is associated with aggressive features and modulates TORC1 complex activation in lung carcinoids.

Ida Rapa, Arianna Votta, Gaia Gatti, Stefania Izzo, Nicola Lo Buono, Elisa Giorgio, Simona Vatrano, Francesca Napoli, Aldo Scarpa, Giorgio Scagliotti and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Ida RapaDepartment of Oncology at San Luigi Hospital, University of Turin, Turin, Italy.
Arianna VottaDepartment of Oncology at San Luigi Hospital, University of Turin, Turin, Italy.
Gaia GattiDepartment of Oncology at San Luigi Hospital, University of Turin, Turin, Italy.
Stefania IzzoDepartment of Oncology at San Luigi Hospital, University of Turin, Turin, Italy.
Nicola Lo BuonoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Elisa GiorgioDepartment of Medical Sciences, University of Turin, Turin, Italy.
Simona VatranoDepartment of Oncology at San Luigi Hospital, University of Turin, Turin, Italy.
Francesca NapoliDepartment of Oncology at San Luigi Hospital, University of Turin, Turin, Italy.
Aldo ScarpaARC-NET Applied Research on Cancer Centre at Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy.
Giorgio ScagliottiDepartment of Oncology at San Luigi Hospital, University of Turin, Turin, Italy.
Mauro PapottiDepartment of Oncology at San Luigi Hospital, University of Turin, Turin, Italy.
Marco VolanteDepartment of Oncology at San Luigi Hospital, University of Turin, Turin, Italy.
University of Turin · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMammalian target of rapamycin (mTOR) is a promising therapeutic target in advanced lung carcinoid patients. However, the mechanisms of mTOR modulation and of responsiveness to mTOR inhibitors are largely unclear. Our aim was to analyze the expression and functional role of specific miRNAs in lung carcinoids as an alternative mechanism targeting mTOR pathway. EXPERIMENTAL

designSeven miRNAs, selected by bioinformatic tools and literature search, were analyzed in 142 lung neuroendocrine neoplasms (92 carcinoids and a control group of 50 high grade neuroendocrine carcinomas), and compared with mTOR mRNA expression and clinical/pathological parameters. Tissue results were validated

resultsTissutal expression of five miRNAs (miR-99b, miR-100, miR-155, miR-193a-3p, miR-193a-5p) was inversely correlated with mTOR mRNA expression, supporting their role in the negative regulation of mTOR transcription. High expression of miR-100, miR-193a-3p and miR-193a-5p was associated with aggressive features and, for the former two, with shorter time to progression. In H727 and UMC11 lung carcinoid cells, miR-100 modulated mTOR RNA and TORC1 complex protein expression, positively promoted cell migration and negatively influenced cell proliferation. Moreover, miR-100 directly influenced responsiveness of H727 and UMC11 cells to rapamycin.

conclusionsMiR-100 actively participates to the regulation of mTOR expression in lung carcinoids and represents a novel candidate prognostic biomarker for this tumor type; moreover, inhibition of its expression is associated to increased responsiveness to mTOR inhibitors and might represent a novel strategy to sensitize lung carcinoids to these target agents.

Indexed as

lung carcinoidsmiR-100miRNAsmTORrapamycin sensitivity

Identifiers

PMID29938004
PMCPMC6007959
OpenAlexW2806115367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.